SRR8518265
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.570
- G2M_CHECKPOINT+0.440
- MTORC1_SIGNALING+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- UV_RESPONSE_UP+0.350
- ALLOGRAFT_REJECTION+0.300
- INTERFERON_GAMMA_RESPONSE+0.290
- INTERFERON_ALPHA_RESPONSE+0.280
Top 10 suppressed
- APICAL_JUNCTION-0.290
- CHOLESTEROL_HOMEOSTASIS-0.200
- MYOGENESIS-0.190
- UV_RESPONSE_DN-0.190
- ESTROGEN_RESPONSE_EARLY-0.170
- BILE_ACID_METABOLISM-0.160
- APICAL_SURFACE-0.150
- ANDROGEN_RESPONSE-0.110
- HEDGEHOG_SIGNALING-0.100
- COAGULATION-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A14N-01A-31R-A137-07 | — | E | 0.868 |
| 2 | TCGA-A2-A0D0-01A-11R-A00Z-07 | — | E | 0.867 |
| 3 | TCGA-ZF-AA4V-01A-11R-A38B-07 | — | — | 0.857 |
| 4 | DRR168607 | — | — | 0.838 |
| 5 | SRR35579801 | — | E | 0.835 |
| 6 | TCGA-XF-A9T6-01A-11R-A42T-07 | — | — | 0.830 |
| 7 | B1A2365C-5491-4E85-AE7E-97B9DB8FF8D1 | — | — | 0.830 |
| 8 | SRR8518159 | — | E | 0.830 |
| 9 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.829 |
| 10 | SRR12696741 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.350 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |